Your browser doesn't support javascript.
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
Khamis, Faryal; Al Naabi, Hanan; Al Lawati, Adil; Ambusaidi, Zaiyana; Al Sharji, Mariam; Al Barwani, Umkulthum; Pandak, Nenad; Al Balushi, Zakariya; Al Bahrani, Maher; Al Salmi, Issa; Al-Zakwani, Ibrahim.
  • Khamis F; Infection Diseases Unit, Department of Medicine, Royal Hospital, Muscat, Oman. Electronic address: khami001@gmail.com.
  • Al Naabi H; Acute Medicine Unit, Department of Medicine, Royal Hospital, Muscat, Oman. Electronic address: Hananhamed4141@gmail.com.
  • Al Lawati A; Acute Medicine Unit, Department of Medicine, Royal Hospital, Muscat, Oman. Electronic address: dr.fadhlani@hotmail.com.
  • Ambusaidi Z; Acute Medicine Unit, Department of Medicine, Royal Hospital, Muscat, Oman. Electronic address: z_ambusaidi@hotmail.com.
  • Al Sharji M; Department of Nursing, Royal Hospital, Muscat, Oman. Electronic address: Hoodmood7@gmail.com.
  • Al Barwani U; Department of Pharmacy, Royal Hospital, Muscat, Oman. Electronic address: umkulthum@yahoo.com.
  • Pandak N; Infection Diseases Unit, Department of Medicine, Royal Hospital, Muscat, Oman. Electronic address: npandak@gmail.com.
  • Al Balushi Z; Infection Diseases Unit, Department of Medicine, Royal Hospital, Muscat, Oman. Electronic address: zak077@gmail.com.
  • Al Bahrani M; Department of Anesthesia and Critical Care, Royal Hospital, Muscat, Oman. Electronic address: dr.mjalbahrani@gmail.com.
  • Al Salmi I; Department of Nephrology, Royal Hospital, Muscat, Oman. Electronic address: isa.al.salmi@gmail.com.
  • Al-Zakwani I; Department of Pharmacology & Clinical Pharmacy, College of Medicine & Clinical Pharmacy, Sultan Qaboos University, Muscat, Oman. Electronic address: ial_zakwani@yahoo.com.
Int J Infect Dis ; 102: 538-543, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-917312
ABSTRACT

OBJECTIVE:

To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia.

METHODS:

A randomized, open-label controlled trial of oral favipiravir in adults hospitalized with moderate to severe COVID-19 pneumonia from June 22nd 2020 to August 13th 2020 was conducted. Patients were randomly assigned to receive either a combination of favipiravir with interferon beta-1b by inhalation aerosol or hydroxychloroquine (HCQ). The outcome endpoints included improvement in inflammatory markers, lower length of hospital stay (LOS), discharges and lower overall 14-day mortality.

RESULTS:

A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir and 51% (n = 45) assigned HCQ. The overall mean age was 55 ± 14 years and 58% (n = 52) were males. There were no significant differences in the inflammatory biomarkers at hospital discharge between the two groups; C-reactive protein (p = 0.413), ferritin (p = 0.968), lactate dehydrogenase (p = 0.259) and interleukin 6 (p = 0.410). There were also no significant differences between the two groups with regards to the overall LOS (7 vs 7 days; p = 0.948), transfers to the ICU (18.2% vs 17.8%; p = 0.960), discharges (65.9% vs 68.9%; p = 0.764) and overall mortality (11.4% vs 13.3%; p = 0.778).

CONCLUSIONS:

No differences in clinical outcomes were found between favipiravir plus inhaled interferon beta-1b and hydroxychloroquine in adults hospitalized with moderate to severe COVID-19 pneumonia.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Interferon beta-1b / Amides / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Interferon beta-1b / Amides / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article